Respiratory Distress Syndrome, Newborn Clinical Trial
Official title:
Delivery Room Management of Premature Infants at High Risk of Respiratory Distress Syndrome
The best mode of delivery room stabilization for premature infants at high risk for respiratory distress syndrome is unknown. The protocol evaluates the impact of three distinct methods of post-delivery stabilization and subsequent early respiratory care on chronic lung disease and survival in premature infants at high risk for respiratory distress syndrome.
The "Delivery room management of premature infants at high risk of respiratory distress syndrome" protocol compares three distinct methods of post-delivery stabilization and subsequent early respiratory care on chronic lung disease and survival in premature infants at high risk of respiratory distress syndrome. The three approaches to post-delivery care include: 1. Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support. 2. Early stabilization on nasal continuous positive airway pressure (NCPAP) with selective intubation and surfactant administration for clinical indications. 3. Intubation, prophylactic surfactant administration shortly after delivery and rapid extubation to nasal CPAP. The primary null hypothesis for this study is that no difference will be found in chronic lung disease and/or mortality at 36 weeks adjusted age in premature infants at high risk of RDS, depending on the method of post-delivery stabilization. The study is a randomized, multicenter trial conducted at participating Vermont Oxford Network Centers. Participating centers will demonstrate competency in the use of nasal CPAP by successfully completing a web-based, educational program and utilizing nasal CPAP in a minimum of 20 infants in their NICU. Infants likely to be delivered to women presenting to a participating Vermont Oxford Network Center at high risk of premature delivery at gestational age 26 + 0 to 29 + 6 weeks will be eligible for inclusion. Specific inclusion criteria that must be met prior to randomization include: 1. imminent delivery 2. no potentially life-threatening congenital anomaly or genetic syndrome 3. no known lung maturity 4. antenatal steroid status known 5. written and informed consent obtained prior to delivery. Exclusion criteria will include: 1. stillborn infants (Apgar score of 0 at one minute of age) or 2. infants noted to have a potentially life-threatening congenital anomaly or genetic syndrome noted immediately after delivery. Eligible infants will have consent obtained prior to delivery. They will be stratified into two groups: 26 + 0 to 27 + 6 weeks gestation and 28 + 0 to 29 + 6 weeks gestation. Shortly before delivery, infants will be randomized to one of the three stabilization strategies detailed below: 1. Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support (PS group). 2. Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications (NCPAP group). 3. Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP (ISX group). Infants requiring intubation for respiratory failure during this study (in any of the three groups) may be stabilized on either conventional or high-frequency ventilation. Specific criteria regarding target ranges for blood gases and indications for extubation, subsequent surfactant dosing, management of extubation, and criteria for reintubation, are all detailed in the protocol. The primary outcome measure is chronic lung disease (defined as documented requirement for supplemental oxygen or respiratory support) or mortality at 36 weeks adjusted age. Secondary outcome measures include a variety of clinical outcomes, as well as issues regarding duration of hospital stay and other resource utilization. Long-term outcomes will be measured by a health care questionnaire at two years of age. A sample size of over 895 infants will be required to demonstrate a 25% reduction in the risk of chronic lung disease at 36 weeks adjusted age. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01206946 -
Efficacy of Antenatal Steroids in Reducing Respiratory Morbidities in Late Preterm Infants
|
Phase 2 | |
Completed |
NCT00739115 -
The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study
|
N/A | |
Terminated |
NCT00486395 -
Will CPAP Reduce Length Of Respiratory Support In Premature Infants?
|
Phase 3 | |
Completed |
NCT01242462 -
Feasibility of Mid-frequency Ventilation in Newborns With RDS: Randomized Crossover Pilot Trial
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT02050971 -
Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates
|
Phase 1 | |
Completed |
NCT00486850 -
Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress
|
Phase 4 | |
Terminated |
NCT00005776 -
Inhaled Nitric Oxide Study for Respiratory Failure in Newborns
|
Phase 3 | |
Completed |
NCT04500353 -
Routine Or Selective Application of a Face Mask for Preterm Infants at Birth: the ROSA Trial
|
N/A | |
Completed |
NCT05796128 -
NIPPV vs.nCPAP During LISA Procedure
|
N/A | |
Withdrawn |
NCT02835209 -
Positioning During SBT in NICU Infants
|
N/A | |
Terminated |
NCT01467076 -
Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)
|
Phase 2 | |
Completed |
NCT00828243 -
Genetic Regulation of Surfactant Deficiency
|
||
Completed |
NCT00556738 -
Intrapulmonary Percussive Ventilation (IPV) Versus Nasal Continuous Positive Airway Pressure Ventilation (nCPAP) in Transient Respiratory Distress of the Newborn
|
N/A | |
Not yet recruiting |
NCT05594030 -
Thoracic Fluid Content by Electric Bioimpedance Versus Lung Ultrasound in Preterm Neonates With Respiratory Distress
|
||
Completed |
NCT02332304 -
Amniotic Fluid Optical Density Determination as a Test for Assessment of Fetal Lung Maturity.
|
Phase 3 | |
Withdrawn |
NCT00598429 -
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
|
Phase 2 | |
Completed |
NCT04137783 -
ABCA3 Gene and RDS in Late Preterm and Term Infants
|
||
Completed |
NCT01941524 -
Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations
|
Phase 4 | |
Completed |
NCT01102543 -
Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)
|
N/A | |
Completed |
NCT00501982 -
Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study
|
Phase 4 |